Journals / Journal of Mood Disorders / 2016 / Cilt: 6 - Sayı: 4

Paliperidone palmitate and lithium induced neuroleptic malignant syndrome in a bipolar disorder patient: a case report

Bipolar Bozukluklu Bir Hastada Paliperidon Palmitat ve Lityum İle İlişkili Nöroleptik Malign Sendrom: Bir Olgu Sunumu

Pages
227–229
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To the best of our knowledge, this case is the first to report the NMS arising from the use of paliperidone palmitate and lithium in a patient with bipolar disorder.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic Malignant Syndrome (NMS); is a rare, idiosyncratic adverse reaction which usually occurs with antipsychotic treatment.
📊
Key Findings & Data:In this case report, we present the manifestation of NMS in a 21-year-old-man with bipolar disorder, after addition of paliperidone palmitate and lithium.
💡
Conclusion & Impact:To the best of our knowledge, this case is the first to report the NMS arising from the use of paliperidone palmitate and lithium in a patient with bipolar disorder.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic Malignant Syndrome (NMS); is a rare, idiosyncratic adverse reaction which usually occurs with antipsychotic treatment. It is defined as fever, autonomic instability, extrapyramidal syndrome and altered mental state. Elevated serum creatine kinase level, impaired liver and kidney function tests, leukocytosis, and electrolyte disturbance may be the accompanying laboratory features. In this case report, we present the manifestation of NMS in a 21-year-old-man with bipolar disorder, after addition of paliperidone palmitate and lithium. To the best of our knowledge, this case is the first to report the NMS arising from the use of paliperidone palmitate and lithium in a patient with bipolar disorder.

Özet

Nöroleptik Malign Sendrom (NMS); nadir görülen, genellikle antipsikotik kullanımıyla oluşan, idiyosenkratik istenmeyen bir ters etkidir. Yüksek ateş, otonomik dengesizlik, ekstrapiramidal bulgular ve bilinç değişiklikleri ana belirtilerdir. Laboratuvar bulgularında kreatin kinaz düzeyinde yükselme, lökositoz ve elektrolit bozukluğu, karaciğer ve böbrek fonksiyonlarında bozulma görülebilir. Bu olgu bildiriminde bipolar bozukluğu olan 21 yaşındaki erkek hastada lityum ve paliperidon palmitat kullanırken ortaya çıkan NMS sunulmuştur. Bizim bilgimize göre, bu olgu bipolar bozukluğu olan hastalarda paliperidon palmitat ve lityum kullanımından kaynaklanan NMS olarak bildirilen ilk olgudur.

🔖

Cite This Article

İSPİR, M., ATEŞ, M. A., TÜTÜNCÜ, R., BALIBEY, H., ÖGE, C., YILAN, Y., BAŞOĞLU, C., ALGÜL, A. (2022). Paliperidone palmitate and lithium induced neuroleptic malignant syndrome in a bipolar disorder patient: a case report. Journal of Mood Disorders, Cilt: 6 - Sayı: 4, 227–229. https://ajindex.com/articles/564537

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Canbek O, Sevim ME, Oncu F, Soysal H. Neuroleptic malignant syndrome: a case treated with bromocriptine. Düşünen Adam: The Journal Of Psychiatry and Neurological Sciences. 2010;23:210-4.
  2. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. Prim Care Companion J Clin Psychiatry. 2007;9:148-50.
  3. Orhan FÖ, Zencirci B, Öksüz H, Bayır A, Karaaslan MF. Nöroleptik malign sendrom: Tedaviye sertralin eklenmesi sonrası ortaya çıkan bir olgunun sunumu. Klinik Psikofarmakoloji Bulteni. 2007;17:30- 3. Herken H, Kaya N, Aşkın R, Kucur R. Nöroleptik malign sendrom: 5 Olgu. Klinik Psikiyatri Dergisi. 1998;1:120-4.
  4. Dimitrakopoulos S, Konstantakopoulos G. Pharmacological agents under research for the maintenance treatment in bipolar disorder. Psychiatriki. 2015;26:169-80.
  5. Kadiroğlu AK, Ebik B, Kaya Ö, Yıldırım S, Bez Y. Nöroleptik malign sendrom tanılı üç olgu: Ayırıcı tanı ve predispozan nedenler. Yoğun Bakım Derg. 2011;3:67-70.
  6. Tekelioğlu ÜY, Yıldız İ, Bayır H, Demirhan A, Akkaya A, Duran A, Koçoğlu H. Nöroleptik Malign Sendrom: Olgu Sunumu. Turk J Anaesth Reanim. 2012;40:329-31.
  7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, J, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.